Skip to main content

Logistic Growth of EHR users under MeaningfulUse

Logistic Growth Curve (courtesy of Wikipedia)
Students of economics will likely be familiar with the logistic growth curve.  The curve has been used to model population growth, in modeling of stochastic processes and adoption of new technology. The early part of the curve is nearly exponential in the early stages, then moves to linear, and finally into exponential decay.

Recently, HHS released data on Meaningful Use attestations (through November of last year) on Data.gov. Brian Ahier posted a couple of extractions from this data earlier today.  The data includes the following elements:


Variable Name Definition
Vendor Name Name of EHR vendor
EHR Product Name Name of EHR product
EHR Product Version Version of EHR product
Product Classification Whether product meets all Meaningful Use requirements (Complete) or meets only part of the Meaningful Use requirements (Modular)
Product Setting Practice setting for which product is designed for (Ambulatory or Inpatient)
Attestation month Month that the provider successfully attested to MU
Business State/Territory Business location of provider who successfully attested to MU (state/territory)
Provider Type Whether attestor was an eligible professional (EP) or eligible hospital (Hospital)
Specialty Specialty or provider type
Program Year Year of EHR Incentive Program
Payment Year Payment year of EHR Incentive Program
Program Type Whether the attestor registered under Medicare or Medicare/Medicaid
ID Unique ID for each Attestor

I put together a quick pivot chart report which showed the number of attestations by month for Meaningful Use, and looked at the growth trend.  Here is how it looked:

And here is the raw data for this chart:

Month Attestations
4 506
5 812
6 1045
7 1461
8 2268
9 3774
10 5754
11 7341


What this chart clearly shows is that we are still in the exponential growth stage for attestations.  I found some information on logistic curve fitting data.  It required an estimation of the saturation point for the population, so I looked up the number of physician practices from Wikipedia and applied it to the model.  Given the the disparity between EP attestations (21,461) and Hospital attestations (1,500), I figured that an estimate of 250,000 was sufficient.

What I wanted to find out by this was when MU would be "done" (i.e., CMS would be "saturated" with attestations), and my results were rather surprising.  So I went back and checked it again with two other estimates (125K and 500K).  Then I took the 95% confidence interval on my low and high estimates.  I plotted it out so that you could see the range of possible answers here:



What this shows me is that by mid-year of 2012, we'll be halfway to saturation, and by the end of 2013, we'll have reached saturation. And if I'm too high on my estimate of providers, it will be by October of 2012, and if I'm to low it will be by October of 2013.

Now, my 95% bands were on the transformed linear equation, so I don't know how that impacts things with respect to confidence bands (I could figure it out, but I'm not that deeply interested).  What this tells me is that Meaningful Use, rather than being "off schedule" appears to be ahead of schedule.  I still don't know if I believe that.

One thing this model doesn't account for is how many providers attesting were already EHR users, and so were ready to attest, vs. those that have yet to adopt.  I suspect that the market is just a bit more complex than a simple logistic curve can account for, but even if it is, there's still another whole year before "Meaningful Use" is over using the figures I went with.  I'd stick with the "ahead of schedule" estimate at this point.

So, 2012 should see EHR adoption rates at several multiples of the current rate.  We'll look at the numbers again when they've released new data to see how things are going.

Comments

Popular posts from this blog

clip on magnetic sunglasses visit here

Save with prescription glasses and sunglasses. Prescription eyeglasses with magnetic clip on sunglasses. A wide selection of colors and styles for every budget! -GlassesPoint. Prescription eyeglasses with magnetic clip on sunglasses. A wide selection of colors and styles for every budget! Free magnetic clip on with every pair of glasses.  The operator should contact lens Plano glasses a few days of Sun and Rx on the other person. Many people choose single vision lenses, designed for a specific use, such as prescription sunglasses. Clip-ons magnetic magnetic clip ons often come with their prescription glasses frames. Prescription glasses Goggles4u dollars from 29.99 with free shipping. Takumi neodium magnet glass features recipes that are light, strong and in. The combination of some normal prescription glasses and a pair of polarized glasses that glare-resistant to outdoor activities. clip on magnetic sunglasses visit here

The Tragedy of Underfunded Mental Health Care

Today’s Managing Health Care Costs Indicator is   19,900 The NY Times  on Friday had a deeply disturbing article on a murder that stunned the mental health community here in Massachusetts.    A long-term schizophrenic man, off his medicine and spiraling into incoherence, killed a young female counselor who was the sole worker at a group home in a Boston suburb.   His mother, who works at a Boston teaching hospital, was frantic with worry as her adult son, who had been arrested for assault multiple times, was becoming more psychotic.    It was hard for her to get anyone’s attention. The counselor was the first in her family to get a college degree, and had just decided to go to nursing school.    Now she’s dead – and her family had trouble scraping together the resources for a burial.   The schizophrenic will be imprisoned for the rest of his life – which ironically could be the best chance for him to get appropriate medical care. Both...

How a Well-Intended FDA Policy on Colchicine is Harming Patients

The road to hell is paved with good intentions. The FDA has reaffirmed the truth of this aphorism with its policy about Colchicine. Here's the story: I recently spoke with a friend who has a family member suffering from Familial Mediterranean Fever (FMF), an auto-inflammatory disorder, most commonly seen in eastern Mediterranean populations. The condition is characterized by recurrent painful inflammation of the abdomen, chest and joints, accompanied by fever. FMF is associated with mutation of a gene on chromosome 16 involved with regulating Pyrin, a protein that is part of the inflammatory response. There is no specific test for the disease. Diagnosis is made on the basis of symptoms, family history, and ruling out other conditions. Since the 1960s, Colchicine, a plant extract first used for treatment of gout two thousand years ago, has been used for treating FMF. As an ancient treatment widely used prior to formation of the FDA, Colchicine did not require FDA approval as a new ...